Polygenetic risk score: Polygenetic risk score assessment for breast cancer
Study summary
The study aims to evaluate the impact of implementing population-based genetics testing strategy for breast cancer precision prevention using the polygenic risk score and monogenic pathogenic variant (MPV) testing in the Norwegian healthcare setting.
Eligibility
Sex
FEMALE
Min age
40 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:
* Women referred for clinical mammography in the Vestre Viken Breast Centre
* Breast density BI-RADS a or d
* 40-50 y.o.
Exclusion Criteria:
* Prior history of breast cancer or premalignant breast disease
* Prior genetic counselling/testing
Primary outcome measure(s)
Assessment of breast cancer risk by polygenetic risk score in the study population — 10 years Polygenetic breast cancer risk score (PRS) as a numeric value with 10 percentile, as absolute 10-year breast cancer risk, and as relative risk compared with average women at the same age
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
